129
Views
10
CrossRef citations to date
0
Altmetric
Original Research

Biodegradable Eri silk nanoparticles as a delivery vehicle for bovine lactoferrin against MDA-MB-231 and MCF-7 breast cancer cells

, , , , &
Pages 25-44 | Published online: 21 Dec 2015
 

Abstract

This study used the Eri silk nanoparticles (NPs) for delivering apo-bovine lactoferrin (Apo-bLf) (~2% iron saturated) and Fe-bLf (100% iron saturated) in MDA-MB-231 and MCF-7 breast cancer cell lines. Apo-bLf and Fe-bLf-loaded Eri silk NPs with sizes between 200 and 300 nm (±10 nm) showed a significant internalization within 4 hours in MDA-MB-231 cells when compared to MCF-7 cells. The ex vivo loop assay with chitosan-coated Fe-bLf-loaded silk NPs was able to substantiate its future use in oral administration and showed the maximum absorption within 24 hours by ileum. Both Apo-bLf and Fe-bLf induced increase in expression of low-density lipoprotein receptor-related protein 1 and lactoferrin receptor in epidermal growth factor (EGFR)-positive MDA-MB-231 cells, while transferrin receptor (TfR) and TfR2 in MCF-7 cells facilitated the receptor-mediated endocytosis of NPs. Controlled and sustained release of both bLf from silk NPs was shown to induce more cancer-specific cytotoxicity in MDA-MB-231 and MCF-7 cells compared to normal MCF-10A cells. Due to higher degree of internalization, the extent of cytotoxicity and apoptosis was significantly higher in MDA-MB-231 (EGFR+) cells when compared to MCF-7 (EGFR−) cells. The expression of a prominent anticancer target, survivin, was found to be downregulated at both gene and protein levels. Taken together, all the observations suggest the potential use of Eri silk NPs as a delivery vehicle for an anti-cancer milk protein, and indicate bLf for the treatment of breast cancer.

Supplementary materials

Figure S1 Fold change in gene expressions for MDA-MB-231 cells.

Note: Representative analysis for quantitative PCR analysis of key apoptotic markers and lactoferrin receptors.

Figure S1 Fold change in gene expressions for MDA-MB-231 cells.Note: Representative analysis for quantitative PCR analysis of key apoptotic markers and lactoferrin receptors.
Figure S1 Fold change in gene expressions for MDA-MB-231 cells.Note: Representative analysis for quantitative PCR analysis of key apoptotic markers and lactoferrin receptors.

Figure S2 Fold change in gene expressions for MCF-7 cells.

Note: Representative analysis for quantitative PCR analysis of key apoptotic markers and lactoferrin receptors.

Figure S2 Fold change in gene expressions for MCF-7 cells.Note: Representative analysis for quantitative PCR analysis of key apoptotic markers and lactoferrin receptors.
Figure S2 Fold change in gene expressions for MCF-7 cells.Note: Representative analysis for quantitative PCR analysis of key apoptotic markers and lactoferrin receptors.

Acknowledgments

The authors would like to thank the Australia–India Strategic Research Fund (grant AISRF BF030016) and the National Health and Medical Research Council (grant NHMRC APP1050286) for financial support. Support from the Australian Research Council (ARC), through an ARC Discovery Grant (number DP120100139), is also acknowledged.

Disclosure

The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. No writing assistance was utilized in the production of this manuscript.